{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"55","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Patients will be followed according to response criteria as referenced in BMT SOP \"Standards of Therapy\" last updated 2008. Clinical Response = CR + PR.\n\nComplete Response Requires all of the following:\n\n* Serum and urine negative for monoclonal proteins by immunofixation\n* Normal free light chain ratio\n* Plasma cells in marrow \\< 5%\n\nPartial Response (PR) Requires any of the following:\n\n\\- ≥ 50% reduction in current serum monoclonal protein levels \\> 0.5 g/dL or urine light chain levels \\> 100 mg/day with a visible peak or free light chain levels \\> 10mg/dL\n\nProgressive Disease (PD) Requires any of the following:\n\n* If progressing from CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double)\n* If progressive from PR or SD, ≥ 50% increase in the serum M protein to \\> 0.5 g/dL,or ≥ 50% increase in urine M protein to \\> 200mg/day with visible peak present.\n* Free light chain increase of ≥ 50% to","dispersionType":"95% Confidence Interval","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\ntacrolimus: Given IV or PO\n\nmycophenolate mofetil: Given IV or PO\n\nmethotrexate: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo PBSCT","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic PBSCT)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"In the first 100 days from day 0 of transplant","title":"Clinical Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}